Streck CE-marked AMR surveillance kits
April 2020—Streck released CE-marked ARM-D kits for the OXA, MCR, and TEM/SHV/GES gene families.
Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
EC approves venetoclax + obinutuzumab for CLL
April 2020—Roche announced that the European Commission has approved Venclyxto (venetoclax) in combination with Gazyvaro (obinutuzumab) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia.
Quest selects Siemens Atellica for IA testing
April 2020—Siemens Healthineers announced it was selected by Quest Diagnostics to be Quest’s preferred supplier for immunoassay testing. As part of the multiyear agreement, Quest will deploy up to 120 Atellica Solution immunoassay analyzers in 19 esoteric and core laboratories in the United States.
FDA approves first drug for children with peanut allergy
April 2020—The U.S. Food and Drug Administration approved Palforzia (Peanut [Arachis hypogaea] Allergen Powder-dnfp) to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts. Treatment with Palforzia (Aimmune Therapeutics) may be initiated in individuals ages four through 17 years with a confirmed diagnosis of peanut allergy and may be continued in individuals four years of age and older. Those who take Palforzia must continue to avoid peanuts in their diets.
FDA clears Lumipulse G CA19-9-N assay
April 2020—Fujirebio Diagnostics received FDA clearance of its Lumipulse G1200 CA19-9-N chemiluminescent enzyme immunoassay for use on the Lumipulse G1200 system. The assay provides the quantitative measurement of CA 19-9 in human serum or plasma and is for use as an aid in the management of patients diagnosed with cancer of the exocrine pancreas.
Agilent microarrays for pre-, postnatal research
April 2020—Agilent Technologies introduced three microarrays to meet the needs of cytogenetic laboratories conducting prenatal and postnatal research.
Epredia introduces slide printing system at USCAP
April 2020—Epredia introduced its SlideMate Pro slide printing system at USCAP, Feb. 29–March 5, in Los Angeles. It was the first time the company attended USCAP; Epredia was established in July 2019 through an acquisition by PHC Group from Thermo Fisher Scientific.
Thermo Fisher expanded carrier screening kits
April 2020—Thermo Fisher Scientific introduced the Ion Torrent CarrierSeq ECS Kit for the Ion GeneStudio S5 system. The next-generation-sequencing–based solution consolidates a multiplatform approach into a single solution.
CLSI publishes 30th edition of M100
April 2020—The Clinical and Laboratory Standards Institute has published its annually updated antimicrobial susceptibility testing supplement, “M100: Performance Standards for Antimicrobial Susceptibility Testing, 30th ed.” M100 is available as part of a package with either “M02: Performance Standards for Antimicrobial Disk Susceptibility, 13th ed.” or “M07: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 11th ed.,” or all three documents can be purchased together. A free, read-only web version of M100 is available at https://j.mp/2UEHgtj.
Verichem standard kits for ethanol, urine uric acid
March 2020—Verichem Laboratories announced the availability of its ethanol standard kits. The protein-based, liquid standards are intended for calibration or calibration verification of serum ethanol test systems. The product also contains lactate, salicylate, and acetaminophen in a known linear relation and may be used to determine the linearity, sensitivity, and reportable range for these analytes as well. The reference materials are free of surfactants, glycols, azide, and other interfering substances. The kit contains a six-level set with 5.0 mL of each level.